RT Journal Article
SR Electronic
T1 Pemetrexed Combined with Platinum-based Chemotherapy for Advanced Malignant Peritoneal Mesothelioma: Retrospective Analysis of Six Cases
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 215
OP 220
VO 34
IS 1
A1 NAKANO, MICHITAKA
A1 KUSABA, HITOSHI
A1 MAKIYAMA, AKITAKA
A1 ARIYAMA, HIROSHI
A1 ARITA, SHUJI
A1 ODA, HISANOBU
A1 ESAKI, TAITO
A1 TAKAYOSHI, KOTOE
A1 UCHINO, KEITA
A1 TAMURA, SHINGO
A1 KUMAGAI, HOZUMI
A1 IWAMA, EIJI
A1 SHIRAKAWA, TSUYOSHI
A1 MITSUGI, KENJI
A1 TAKAISHI, SHIGEO
A1 AKASHI, KOICHI
A1 BABA, EISHI
YR 2014
UL http://ar.iiarjournals.org/content/34/1/215.abstract
AB Background: Malignant peritoneal mesothelioma (PM) is an extremely rare disease. Pemetrexed and platinum have been used for advanced PM following malignant pleural mesothelioma (PLM). Because PM differs considerably from PLM in clinical features, the efficacy and safety of these therapies have yet to be established. Patients and Methods: Six Japanese patients with PM who had been treated with pemetrexed-based chemotherapy in four Institutions were retrospectively identified. Treatment response, progression-free survival, and overall survival were examined. Toxicities of therapy were also evaluated. Results: Three patients with mild ascites achieved clinical benefits (one with partial response and two with stable disease). Treatments with reduced cisplatin or carboplatin for patients with massive ascites were safely performed. Median PFS and OS were 7.2 and 13.1 months, respectively. Grade 3 hematological toxicities appeared in two patients with massive ascites. Conclusion: Selection of chemotherapy based on the patient's condition, such as ascites, might be important for advanced PM.